Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV

EBioMedicine

Volumn 2, Issue 4, 2015, Pages 334-340

  Sullivan, Zuri A ^a,b   Wong, Emily B ^a,c   Ndung'u, Thumbi ^a,d,e,f   Kasprowicz, Victoria O ^a,d,e   Bishai, William R ^a,b  

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

HIV; Immune activation; Inflammation; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD38 ANTIGEN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUBERCULOSIS;

EID: 84949659705     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.03.005     Document Type: Article

References (41)

1. Adekambi T., Ibegbu C.C., Kalokhe A.S., Yu T., Ray S.M., Rengarajan J. Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One 2012, 7:e36046.
2. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., Schnappinger D., Wilkinson R.J., Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009, 7:845-855.
3. Beltran L.M., Munoz Hernandez R., De Pablo Bernal R.S., Garcia Morillo J.S., Egido J., Noval M.L., Ferrando-Martinez S., Blanco-Colio L.M., Genebat M., Villar J.R., Moreno-Luna R., Moreno J.A. Reduced sTWEAK and Increased sCD163 levels in HIV-Infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One 2014, 9:e90541.
4. Bloom C.I., Graham C.M., Berry M.P., Wilkinson K.A., Oni T., Rozakeas F., Xu Z., Rossello-Urgell J., Chaussabel D., Banchereau J., Pascual V., Lipman M., Wilkinson R.J., O'Garra A. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012, 7:e46191.
5. Bloom C.I., Graham C.M., Berry M.P., Rozakeas F., Redford P.S., Wang Y., Xu Z., Wilkinson K.A., Wilkinson R.J., Kendrick Y., Devouassoux G., Ferry T., Miyara M., Bouvry D., Valeyre D., Gorochov G., Blankenship D., Saadatian M., Vanhems P., Beynon H., Vancheeswaran R., Wickremasinghe M., Chaussabel D., Banchereau J., Pascual V., Ho L.P., Lipman M., O'Garra A. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013, 8:e70630.
6. Boulware D.R., Hullsiek K.H., Puronen C.E., Rupert A., Baker J.V., French M.A., Bohjanen P.R., Novak R.M., Neaton J.D., Sereti I., Group, I.S. Higher levels of CRP, d-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 2011, 203:1637-1646.
7. Crane M., Avihingsanon A., Rajasuriar R., Velayudham P., Iser D., Solomon A., Sebolao B., Tran A., Spelman T., Matthews G., Cameron P., Tangkijvanich P., Dore G.J., Ruxrungtham K., Lewin S.R. Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. J. Infect. Dis. 2014, 210:745-751.
8. De Almeida A.S., Fiske C.T., Sterling T.R., Kalams S.A. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin. Vaccine Immunol. 2012, 19:45-52.
9. Deeks S.G., Kitchen C.M., Liu L., Guo H., Gascon R., Narvaez A.B., Hunt P., Martin J.N., Kahn J.O., Levy J., Mcgrath M.S., Hecht F.M. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004, 104:942-947.
10. Dillon S.M., Lee E.J., Kotter C.V., Austin G.L., Dong Z., Hecht D.K., Gianella S., Siewe B., Smith D.M., Landay A.L., Robertson C.E., Frank D.N., Wilson C.C. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014, 7:983-994.
11. French M.A., King M.S., Tschampa J.M., Da Silva B.A., Landay A.L. Serum immune activation markers are persistently increased in patients with HIV infection after 6years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J. Infect. Dis. 2009, 200:1212-1215.
12. Ghesani N., Patrawalla A., Lardizabal A., Salgame P., Fennelly K.P. Increased cellular activity in thoracic lymph nodes in early human latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 2014, 189:748-750.
13. Giorgi J.V., Liu Z., Hultin L.E., Cumberland W.G., Hennessey K., Detels R. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6years of follow-up. J. Acquir. Immune Defic. Syndr. 1993, 6:904-912.
14. Giorgi J.V., Hultin L.E., Mckeating J.A., Johnson T.D., Owens B., Jacobson L.P., Shih R., Lewis J., Wiley D.J., Phair J.P., Wolinsky S.M., Detels R. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus buren or virus chemokine coreceptor usage. J. Infect. Dis. 1999, 179:859-870.
15. Hanifa Y., Grant A.D., Lewis J., Corbett E.L., Fielding K.L., Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int. J. Tuberc. Lung Dis. 2009, 13:39-46.
16. Hasegawa A., Liu H., Ling B., Borda J.T., Alvarez X., Sugimoto C., Vinet-Oliphant H., Kim W.K., Williams K.C., Ribeiro R.M., Lackner A.A., Veazey R.S., Kuroda M.J. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 2009, 114:2917-2925.
17. Hodapp T., Sester U., Mack U., Singh M., Meier T., Wiech E., Fisch P., Ehl S., Sester M. Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide. Eur. Respir. J. 2012, 40:152-160.
18. Houben R.M.G.J., Sumner T., Grant A.D., White R.G. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:5325-5330.
19. Hunt P.W., Martin J.N., Sinclaire, Bredt B., Hagos E., Lampiris H., Deeks S.G. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 2003, 187:1534-1543.
20. Hunt P.W., Cao H.L., Muzoora C., Ssewanyana I., Bennett J., Emenyonu N., Kembabazi A., Neilands T.B., Bangsberg D.R., Deeks S.G., Martin J.N. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011, 25:2123-2131.
21. Hunt P.W., Martin J.N., Sinclair E., Epling L., Teague J., Jacobson M.A., Tracy R.P., Corey L., Deeks S.G. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J. Infect. Dis. 2011, 203:1474-1483.
22. Lawn S.D., Labeta M.O., Arias M., Acheampong J.W., Griffin G.E. Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment. Clin. Exp. Immunol. 2000, 120:483-487.
23. Lawn S.D., Wood R., De Cock K.M., Kranzner K., Lewis J.J., Churchyard G. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect. Dis. 2010, 10:489-498.
24. Mahan C.S., Walusimbi M., Johnson D.F., Lancioni C., Charlebois E., Baseke J., Chervenak K.A., Mugerwa R.D., Havlir D.V., Mayanja-Kizza H., Whalen C.C., Boom W.H., Uganda-Case Western Research, C. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One 2010, 5:e9138.
25. Marchetti G., Tincati C., Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev. 2013, 26:2-18.
26. Marchetti G., Cozzi-Lepri A., Tincati C., Calcagno A., Cecherini-Silberstein F., De Luca A., Antinori A., Castagna A., Puoti M., Monforte A.D. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infect. Dis. 2014, 14:79-87.
27. Mariotti S., Pardini M., Gagliardi M.C., Teloni R., Giannoni F., Fraziano M., Lozupone F., Meschini S., Nisini R. Dormant Mycobacterium tuberculosis fails to block phagosome maturation and shows unexpected capacity to stimulate specific human T lymphocytes. J. Immunol. 2013, 191:274-282.
28. Morgan D., Maude G.H., Malamba S.S., Okongo M.J., Wagner H.-U., Mulder D.W., Whitworth J.A. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997, 350:245-250.
29. Neuhaus J., Jacobs D.R., Baker J.V., Calmy A., Duprez D., La Rosa A., Kuller L.H., Pett S.L., Ristola M., Ross M.J., Shlipak M.G., Tracy R., Neaton J.D. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 2010, 201:1788-1795.
30. Rodrigues D.S.S., Medeiros E.A.S., Weckx L.Y., Bonnez W., Salomão R., Kallas E.G. Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin. Exp. Immunol. 2002, 128:149-154.
31. Sandler N.G., Wand H., Roque A., Law M., Nason M.C., Nixon D.E., Pedersen C., Ruxrungtham K., Lewin S.R., Emery S., Neaton J.D., Brenchley J.M., Deeks S.G., Sereti I., Douek D.C., Group, I.S.S. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 2011, 203:780-790.
32. Sousa A.E., Carneiro J., Meier-Schellersheim M., Grossman Z., Victorino R.M.M. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 2002, 169:3400-3406.
33. Taiwo B., Hunt P.W., Gandhi R.T., Ellingson A., McKenna M., Jacobson J.M., Gripshover B., Bosch R.J. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2013, 63:101-104.
34. Toossi Z., Funderburg N.T., Sirdeshmuk S., Whalen C.C., Nanteza M.W., Johnson D.F., Mayanja-Kizza H., Hirsch C.S. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects. J. Infect. Dis. 2013, 207:1841-1849.
35. Vujkovic-Cvijin I., Dunham R.M., Iwai S., Maher M.C., Albright R.G., Broadhurst M.J., Hernandez R.D., Lederman M.M., Huang Y., Somsouk M., Deeks S.G., Hunt P.W., Lynch S.V., McCune J.M. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med. 2013, 5:193ra91.
36. Wergeland I., Assmus J., Dyrhol-Riise A.M. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand. J. Immunol. 2011, 73:234-242.
37. Wood R., Liang H., Wu H., Middlekoop K., Oni T., Rangaka M.X., Wilkinson R.J., Bekker L.G., Lawn S.D. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int. J. Tuberc. Lung Dis. 2010, 14:406-412.
38. Wood R., Lawn S.D., Caldwell J., Kaplan R., Middelkoop K., Bekker L.G. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One 2011, 6:e25098.
39. World Health Organization W.H. Tuberculosis fact sheet N°104 [Online]. Available:, (Accessed April 13 2014). http://www.who.int/mediacentre/factsheets/fs104/en/.
40. Young D.B., Gideon H.P., Wilkinson R.J. Eliminating latent tuberculosis. Trends Microbiol. 2009, 17:183-188.
41. Zhang X., Hunt P.W., Hammer S.M., Cespedes M.S., Patterson K.B., Bosch R.J. Immune activation while on potent antiretroviral therapy can predict subsequent CD4+ T-cell increases through 15years of treatment. HIV Clin. Trials 2013, 14:61-67.